Pfizer (PFE) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Top 5 Coins for the Maximum Passive Income from Staking by 2024

February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024

Staking is one of the ways that is now being used as a secure and profitable way to earn money without doing anything…
Trading Stocks With AI: A Modern Approach

January 21, 2025 Trading Stocks With AI: A Modern Approach

The stock market can feel overwhelming, especially with its constant ups and downs. Trading stocks with AI is revolutionizing how investors analyze trends,…
Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

The launch of spot Bitcoin (CRYPTO: BTC) exchange-traded funds (ETFs) in January 2025 marked a turning point in the cryptocurrency market. These ETFs…
Advanced Charting Tools For Traders

January 1, 2025 Advanced Charting Tools For Traders

Ever tried deciphering market trends with the intensity of a detective peering over cryptic clues? Enter the realm of Advanced Charting, where complex…
Why Is Trading Important?

December 21, 2024 Why Is Trading Important?

Trade isn’t just figures on a spreadsheet; it’s the pulse of our global community. In 2018, the United States faced a staggering $621…

Pfizer (PFE) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: February 14, 2025 (09:56)

Sector: Healthcare

The share price of Pfizer Inc. (PFE) now

Latest session on the 13th of February for
Pfizer Inc. is positive
Trading Volume: 30612533
Open: 25.49 /  High: 25.74 /  Low: 25.33
Current value: $25.64
What analysts predict: $31.18
52-week High/Low: $30.55 / $23.71
50-Day Moving Average: $26.21 — resistance level today
200-Day Moving Average: $27.88 — resistance level today

News Impact Analyzer

Full report
This Week
Bullish Impact: 5 News: 4 (4/0/0)
Previous Week
Bullish Impact: 1.9 News: 9 (5/1/3)
Two Weeks Ago
Na Impact: Na News: 4 (1/2/1)
Three Weeks Ago
Bearish Impact: 3 News: 2

Analysts predictions

Full report
This Week
Bearish Opinions: 2
Previous Week
Bearish Opinions: 1
Two Weeks Ago
Neutral Opinions: 1
Three Weeks Ago
Neutral Opinions: Na

Analyzing the Most Important PFE news

Pfizer’s Talzenna-Xtandi Combo Delivers Breakthrough in Prostate Cancer Study

Feb 13, 2025
Trend: Bullish
Influence: 8
Positive Phase 3 trial results for Pfizer's Talzenna-Xtandi combo signify a meaningful advancement in prostate cancer treatment, offering potential for increased revenue. The development strengthens Pfizer's oncology portfolio, likely leading to investor optimism. This significant milestone should boost market confidence in PFE, positively impacting its stock price in the near term.

Pfizer's Adcetris Secures Expanded Approval for Lymphoma Treatment

Feb 12, 2025
Trend: Bullish
Influence: 7
The additional FDA approval for Adcetris strengthens Pfizer's oncology portfolio and opens new revenue streams in the competitive cancer treatment market. This development positions Pfizer to gain greater market share, likely boosting investor confidence and stock value in the near term.

Pfizer Partners with Alloy for Cutting-Edge Antibody Discovery

Feb 11, 2025
Trend: Bullish
Influence: 7
The collaboration with Alloy indicates Pfizer's commitment to innovation in biologics, an area of high growth potential. The deal adds to its R&D capabilities, signaling long-term benefits for its pipeline. Positive market sentiment for innovation-driven deals may provide a moderate boost to the stock in the near term, enhancing investor confidence.

Historical and forecast chart of Pfizer stock

The chart below shows the historical price of Pfizer stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.

Long-term forecasts by years.

Pfizer Inc. Analysts predictions review

Pfizer (PFE) faces persistent challenges, including declining revenues from pandemic-related products, increasing competition, and patent expirations on key drugs. While the $43 billion Seagen acquisition bolsters long-term oncology growth, it introduces near-term integration and profitability risks. Additionally, macroeconomic pressures like inflation and rising interest rates exacerbate cost and debt management issues. Despite a strong pipeline, the lack of immediate revenue drivers increases investor caution. These factors collectively signal downward pressure on the stock in the near term.

Pfizer: Evaluating the Risks That Shadow Growth Potential

Trend: Bearish
Feb 12, 2025

Pfizer faces significant challenges stemming from declining revenues in its COVID-19 product portfolio. The reduction in demand for vaccines and antiviral treatments post-pandemic has created a substantial revenue gap, signaling a tougher revenue environment in the near term. The author underscores this revenue headwind as a critical factor applying downward pressure on valuation multiples.

In addition, Pfizer's ambitious $43 billion acquisition of Seagen presents mixed implications. While it bolsters long-term growth in oncology pipelines, the high cost and initial dilution bring considerable near-term integration risks that could weigh on profitability and cash flow generation.

Pipeline Concerns and Macroeconomic Pressures

Beyond acquisition-related risks, Pfizer’s reliance on its broader product pipeline and R&D productivity remains a concern. A failure to deliver innovative blockbuster drugs could magnify investor uncertainty, particularly as patents on key legacy drugs are set to expire in the coming years.

Lastly, macroeconomic headwinds, including rising interest rates and inflationary pressures, contribute further to bearish sentiment. These external pressures not only escalate input costs but also amplify refinancing challenges tied to the sizeable debt from recent acquisitions.


Analyst: Hunting Alpha
( Followers: 5786
Articles: 301 )

Pfizer: Weighing Valuation Concerns Amid Strategic Challenges

Trend: Bearish
Feb 10, 2025

Pfizer's current valuation appears stretched, which could limit upside potential for its stock price in the near term. According to the author, the market may have overestimated the company’s ability to sustain its post-pandemic momentum, highlighting risks of a retracement.

Revenue headwinds are evident as pandemic-related tailwinds, such as COVID-19 vaccine sales, continue to wane while the company faces increased competition in its drug portfolio. The author emphasizes that Pfizer’s core growth prospects might not be sufficient to offset these declines without a robust pipeline or new breakthroughs.

Operational Challenges and Strategic Outlook

Pipeline execution remains a critical factor, as investors are closely watching developments in late-stage trials and potential regulatory approvals. While the author acknowledges Pfizer's R&D focus, delays or weaker-than-expected results would exacerbate investor concerns.

Macro factors, including inflationary pressures and rising interest rates, further compound profitability concerns. These external dynamics could weigh on Pfizer’s margins, dampening earnings visibility and amplifying near-term volatility in its stock price.


Analyst: KM Capital
( Followers: 4862
Articles: 159 )

Pfizer Faces Pressure: Strong Q4 Performance Overshadowed by Weak Guidance and Patent Risks

Trend: Bearish
Feb 04, 2025

Pfizer's Q4 financial results demonstrated a robust performance, supported by strong revenues and operational efficiency. However, these positive results have been largely overshadowed by forward-looking concerns highlighted in the company's updated guidance.

Key Drivers of Stock Performance

The company's revised forward guidance indicates significant revenue headwinds, likely tied to a cooling demand for pandemic-related products. This signals weakness in several core revenue streams, which could weigh on the stock in the near term.

Patent expiration concerns further amplify uncertainty, particularly around key blockbuster drugs nearing the end of their exclusivity period. The loss of market exclusivity is expected to severely curtail profit margins if new replacement products fail to adequately offset this gap.

While Pfizer has a robust pipeline of innovative therapies, the timeline for material contribution is considerably distant. Investors may remain cautious given the lack of immediate drivers to compensate for short-term revenue challenges.


Analyst: Brendan O'Boyle
( Followers: 1765
Articles: 123 )
Jan 13, 2025
Pfizer: Strategic Growth Potential Through Dogs of the Dow in 2025
Trend: Bullish

Pfizer's valuation metrics stand out as a key driver for the investment thesis, with the company demonstrating compelling dividend yields and attractive price-to-earnings ratios relative to its peers. These attributes position Pfizer as a deserving candidate for income-focused strategies like Dogs of the Dow, especially as investors seek stable returns amid market uncertainties.

Pipeline and Innovation: The breadth of Pfizer's R&D pipeline and its progress in launching high-impact medications bolsters the long-term growth narrative. The ability to translate these efforts into commercial success could catalyze significant upside if key products meet or exceed market expectations.

The Dogs of the Dow strategy underscores Pfizer's potential as a top pick for 2025, leveraging its standing as a high-dividend-yield Dow Jones component. This approach plays into a value-focused perspective, which is particularly relevant as the market continues to price in economic headwinds and sector rotation impacts.

Analyst: Wise Bull
( Followers: 1318
Articles: 67 )
Jan 08, 2025
Assessing Pfizer's Prospects: Dividend Stability Versus Competitive Challenges
Trend: Neutral

Pfizer's current dividend policy, while offering an attractive yield, lacks the same level of historical stability and growth reliability as some of its competitors. The author highlights this as a concern for income-focused investors because the company's dividend growth rate lags behind peers like Johnson & Johnson, which could weigh on its attractiveness as a defensive stock.

Recent performance challenges tied to post-pandemic revenue normalization, particularly in its COVID-19 product portfolio, create additional headwinds for Pfizer. These pressures are anticipated to impact the company's near-term earnings visibility, making it less appealing to growth-focused investors.

Strategic Positioning Limits Near-Term Momentum

Pfizer's dependence on new pipeline developments and strategic acquisitions to offset patent cliffs introduces a higher level of uncertainty to its outlook. According to the author, while these efforts could pay off in the long term, near-term execution risks could undermine investor confidence in the stock.

The comparative advantage enjoyed by competitors such as Johnson & Johnson in diversified business models further compounds Pfizer's challenges. The competitor's resilience across multiple segments not only strengthens relative valuation but also shifts attention away from Pfizer's more concentrated product strategy.

Analyst: Sensor Unlimited
( Followers: 9089
Articles: 1145 )
Jan 03, 2025
Pfizer: Strategic Insights for Navigating Upcoming Earnings
Trend: Neutral

Pfizer’s near-term performance is underpinned by several critical drivers, including developments in its COVID-19 vaccine portfolio, patent challenges, and pipeline innovation. Analysts have emphasized the uncertainty surrounding revenue growth due to declining demand for Pfizer’s COVID-19 vaccine and antiviral treatments. This revenue deceleration could create headwinds, pressuring the stock in the short term.

Focus on Pipeline and Earnings Strategy

Efforts to offset declining COVID-19-related sales hinge on Pfizer’s ability to advance its non-COVID product pipeline. While the potential for new drug approvals offers long-term upside, immediate gains may be constrained as clinical development and commercialization timelines remain elongated. Moreover, patent expirations on cornerstone products such as Eliquis are a risk that could weigh on future profitability, necessitating proactive portfolio diversification.

On the earnings front, the company’s cost-cutting and share repurchase programs aim to bolster shareholder value amid top-line weakness. However, while these actions demonstrate management's commitment to financial discipline, they may not fully offset the structural revenue challenges in the near term.

Analyst: Fundamental Options
( Followers: 314
Articles: 22 )
Jan 01, 2025
Pfizer's Strategic Revival: Key Catalysts Driving 2025 Growth
Trend: Neutral

Pfizer's growth trajectory appears to hinge on its efforts to diversify revenues and mitigate a post-pandemic lull, particularly as COVID-19-related product sales wane. The company's strategic shift towards expanding its pipeline in oncology, rare diseases, and mRNA technology signals a recalibration aimed at offsetting revenue dependence on its pandemic-era portfolio.

Management's focus on mergers and acquisitions (M&A) to bolster its drug portfolio and fortify long-term earnings potential is a pivotal factor. Recent high-profile acquisitions, such as the purchase of Seagen, reflect Pfizer's emphasis on acquiring capabilities in high-growth therapeutic areas, especially oncology, which is projected to be a significant value driver.

Pipeline Strength and Financial Dynamics

Clinical pipeline developments are expected to emerge as a critical short-term stock price driver. Key milestones for late-stage drug candidates and continued FDA approvals are poised to revive investor confidence, given the diminishing COVID-19 tailwinds.

On the financial side, near-term headwinds exist due to declining free cash flow from reduced COVID-19 vaccine revenues. However, robust capital allocation towards R&D and M&A, complemented by strong balance sheet fundamentals, positions Pfizer to weather this transitional phase effectively.

Analyst: Yiannis Zourmpanos
( Followers: 8537
Articles: 348 )

Comprehensive Analysis of Pfizer (PFE) Stock Market Performance


Our multifaceted analysis of Pfizer's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Pfizer stock?
  • When should I record a loss on Pfizer stock?
  • What are analysts' forecasts for Pfizer stock?
  • What is the future of Pfizer stock?

We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks.

The Bright Future of PFE Stocks: An Unfolding Opportunity

In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.

The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.

Factors Influencing PFE Stock Performance

Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.

Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.

In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.

Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.

There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.

Pfizer Inc. News influencing stock rates

As of now, Panda has combed through 19 news items directly related to PFE from the last 30 days. Out of these, 10 clearly showcase a bullish trend, while 5 display bearish tendencies, and 4 events are neutral.

The strength of the bullish trend outpaces the bearish sentiments by 2.57 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.

The news analyzed fell within the period from Jan 21, 2025, to Feb 13, 2025.

βeta
Feb 10, 2025

Pfizer's Padcev-Combo Boosts Survival in Urothelial Cancer

Trend: Bullish
Influence: 8
The positive clinical results from the Padcev-Keytruda combination as a first-line therapy for urothelial cancer highlight Pfizer’s innovation pipeline and partnerships. This is likely to boost investor sentiment and reflects strong commercial potential, driving PFE's stock price higher in the near term. The breakthrough enhances Pfizer's competitive position in oncology, a high-growth market segment.
Feb 07, 2025

NYC Bird Flu Outbreak Forces Poultry Market Shutdowns

Trend: Neutral
Influence: 3
The bird flu news has a limited direct impact on Pfizer (PFE), as the outbreak doesn't immediately demand significant vaccine production or medical interventions tied to the company's core business. While it signals public health concerns, the market reaction for PFE stock is expected to remain minimal in the short term unless the outbreak escalates significantly.
Feb 06, 2025

Bristol-Myers Squibb Falls Amid Tepid 2025 Outlook

Trend: Bearish
Influence: 6
The disappointing 2025 outlook for Bristol-Myers Squibb suggests broader challenges in the pharma sector that could indirectly pressure PFE's stock through sector spillover effects. While the immediate financials are unrelated, negative sentiment in a key peer raises uncertainty for investors, which may create short-term bearish movements for companies like PFE due to weakened investor confidence.
Feb 04, 2025

Pfizer Accelerates Oncology Leadership with Seagen Integration, Sets Bold 2025 R&D Milestones

Trend: Bullish
Influence: 8
The successful integration of Seagen and strengthened oncology positioning highlight Pfizer's strategic execution and future growth potential. These developments likely boost investor confidence, aligning with its R&D milestone targets for 2025. This positions the stock for upward momentum in the near term, reflecting optimism about innovation and revenue growth in the oncology sector.
Feb 04, 2025

Pfizer Misses the Mark with 2025 Guidance Gap

Trend: Bearish
Influence: 7
Pfizer's 2025 guidance falling short of consensus estimates signals potential headwinds for the company. This could lead to increased investor skepticism and short-term downward pressure on the stock price. While not catastrophic, the gap highlights challenges in meeting market expectations, resulting in a moderately strong impact (7) on investor sentiment and PFE's valuation trajectory.
Feb 04, 2025

Pfizer Posts Strong Q4 Growth Across Key Segments: Oncology +27.4%, Primary Care +26.5%

Trend: Bullish
Influence: 8
Pfizer's significant revenue growth in Primary Care, Specialty Care, and Oncology suggests strong operational performance and demand. This data signals potential for increased investor confidence and upward stock momentum. The standout Oncology growth further bolsters Pfizer's strategic prospects. Key revenue trends strongly position the company to outperform in the near term, justifying the bullish trend and high influence level.
Feb 04, 2025

Pfizer Beats Q4 Earnings but Disappoints with FY2025 Forecast

Trend: Bearish
Influence: 7
While Pfizer's Q4 earnings exceeded expectations, the FY2025 outlook fell short, raising concerns about its future growth trajectory. This mismatch is likely to negatively influence investor sentiment in the short term, as forward guidance often weighs heavier on stock decisions. Potential downward pressure on PFE shares could follow in the absence of compelling long-term catalysts.
Feb 04, 2025

Pfizer Surpasses Q4 Expectations with Strong Earnings and Revenue Growth

Trend: Bullish
Influence: 8
Pfizer's Q4 results beating both EPS and revenue expectations signal strong financial health and operational success. The confirmation of 2025 guidance further boosts investor confidence. This solid performance is likely to drive positive sentiment and demand for Pfizer's stock, leading to potential near-term price appreciation. The influence is substantial but not absolute, rated at 8.
Feb 03, 2025

Pfizer Q4: Anticipated Revenue Surge Draws Market Attention

Trend: Bullish
Influence: 8
Expectations of 21.1% YoY revenue growth and a 360% profit surge due to COVID-19 product demand signal strong performance for Pfizer. These figures are likely to boost investor confidence, driving positive market sentiment and potentially lifting the stock price in the short term. The high growth rates highlight Pfizer's significant role in the pandemic-era healthcare landscape.
Feb 03, 2025

Pfizer's Braftovi Shows Positive Phase 3 Results in Colorectal Cancer Study

Trend: Bullish
Influence: 7
The positive Phase 3 trial results for Braftovi in colorectal cancer represent a significant step forward for Pfizer's oncology portfolio. This development could strengthen investor confidence in the company’s R&D capabilities and drive potential future revenue. However, the market impact depends on broader clinical adoption and regulatory approval, tempering the overall influence slightly.

Trending Themes in the Healthcare Sector

Pfizer daily forecast for a month

Date Target Pes. Opt. Vol., %
Feb 16 26.62 26.19 26.78 2.26
Feb 17 26.57 26.15 27.10 3.63
Feb 18 26.94 26.55 27.56 3.81
Feb 19 26.39 26.09 26.97 3.37
Feb 20 26.66 26.36 27.00 2.43
Feb 21 26.45 25.88 26.99 4.26
Feb 22 26.09 25.60 26.64 4.07
Feb 23 26.35 25.81 26.62 3.15
Feb 24 26.35 26.17 26.81 2.45
Feb 25 26.04 25.56 26.47 3.54
Feb 26 26.05 25.48 26.46 3.83
Feb 27 26.22 25.73 26.51 3.03
Feb 28 26.34 26.04 26.91 3.34
Mar 01 26.79 26.21 27.22 3.86
Mar 02 26.57 25.99 27.10 4.26
Mar 03 27.07 26.91 27.35 1.63
Mar 04 27.23 26.59 27.76 4.39
Mar 05 27.89 27.44 28.52 3.96
Mar 06 28.00 27.62 28.51 3.22
Mar 07 27.56 27.29 28.17 3.24
Mar 08 27.73 27.07 28.02 3.50
Mar 09 26.96 26.38 27.26 3.34
Mar 10 27.25 27.03 27.82 2.93
Mar 11 27.21 26.71 27.54 3.09
Mar 12 27.40 27.16 27.90 2.72
Mar 13 27.79 27.25 28.00 2.75
Mar 14 27.70 27.30 28.04 2.71
Mar 15 27.14 26.89 27.40 1.88
Mar 16 27.18 26.96 27.59 2.36
Mar 17 27.18 26.87 27.45 2.19

Pfizer Daily Price Targets


Pfizer Stock Forecast 02-16-2025.

Forecast target price for 02-16-2025: $26.62.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.207%.
Pessimistic target level: 26.19
Optimistic target level: 26.78

Pfizer Stock Forecast 02-17-2025.

Forecast target price for 02-17-2025: $26.57.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.500%.
Pessimistic target level: 26.15
Optimistic target level: 27.10

Pfizer Stock Forecast 02-18-2025.

Forecast target price for 02-18-2025: $26.94.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.667%.
Pessimistic target level: 26.55
Optimistic target level: 27.56

Pfizer Stock Forecast 02-19-2025.

Forecast target price for 02-19-2025: $26.39.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.259%.
Pessimistic target level: 26.09
Optimistic target level: 26.97

Pfizer Stock Forecast 02-20-2025.

Forecast target price for 02-20-2025: $26.66.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.370%.
Pessimistic target level: 26.36
Optimistic target level: 27.00

Pfizer Stock Forecast 02-21-2025.

Forecast target price for 02-21-2025: $26.45.
Negative dynamics for Pfizer shares will prevail with possible volatility of 4.088%.
Pessimistic target level: 25.88
Optimistic target level: 26.99

PFE (PFE) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Mar. 25.17 24.20 26.80 9.72
Apr. 27.14 25.53 27.83 8.25
May. 27.90 26.24 28.78 8.81
Jun. 26.75 25.88 27.37 5.45
Jul. 24.65 22.94 25.96 11.62
Aug. 23.81 23.12 25.12 7.93
Sep. 22.84 22.06 23.85 7.50
Oct. 21.82 20.89 22.54 7.32
Nov. 21.07 19.69 22.28 11.66
Dec. 20.18 19.31 21.50 10.22

Pfizer forecast for this year


Pfizer Stock Prediction for Mar 2025

An downtrend is forecast for this month with an optimal target price of $25.172. Pessimistic: $24.20. Optimistic: $26.80


Pfizer Stock Prediction for Apr 2025

An uptrend is forecast for this month with an optimal target price of $27.143. Pessimistic: $25.53. Optimistic: $27.83


Pfizer Stock Prediction for May 2025

An uptrend is forecast for this month with an optimal target price of $27.9003. Pessimistic: $26.24. Optimistic: $28.78


Pfizer Stock Prediction for Jun 2025

An downtrend is forecast for this month with an optimal target price of $26.7452. Pessimistic: $25.88. Optimistic: $27.37


Pfizer Stock Prediction for Jul 2025

An downtrend is forecast for this month with an optimal target price of $24.651. Pessimistic: $22.94. Optimistic: $25.96


Pfizer Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $23.808. Pessimistic: $23.12. Optimistic: $25.12


Pfizer Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $22.8438. Pessimistic: $22.06. Optimistic: $23.85


Pfizer Stock Prediction for Oct 2025

An downtrend is forecast for this month with an optimal target price of $21.8158. Pessimistic: $20.89. Optimistic: $22.54


Pfizer Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $21.0697. Pessimistic: $19.69. Optimistic: $22.28


Pfizer Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $20.1784. Pessimistic: $19.31. Optimistic: $21.50



Pfizer (PFE) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 19.47 18.68 20.59 9.28
Feb 20.22 18.77 21.55 12.92
Mar 21.57 21.03 22.13 5.00
Apr 22.11 20.54 23.29 11.79
May 23.23 21.60 24.55 12.01
Jun 24.65 23.96 25.52 6.09
Jul 25.36 24.08 26.71 9.83
Aug 26.66 25.63 27.72 7.53
Sep 25.94 25.17 27.02 6.83
Oct 26.34 24.82 28.07 11.57
Nov 24.02 23.17 25.66 9.69
Dec 24.40 23.06 25.46 9.40

Pfizer (PFE) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 24.91 23.45 26.19 10.44
Feb 26.77 26.29 27.83 5.54
Mar 27.54 26.97 28.38 4.98
Apr 27.76 26.84 29.21 8.13
May 29.34 28.47 30.05 5.27
Jun 27.28 25.49 28.60 10.90
Jul 25.63 24.50 26.37 7.09
Aug 26.65 25.47 28.04 9.15
Sep 26.22 24.92 27.80 10.36
Oct 26.97 26.46 28.67 7.70
Nov 26.83 26.01 28.66 9.27
Dec 26.15 24.46 27.75 11.87

Pfizer information and performance

Pfizer Address

235 E 42ND ST, NEW YORK, NY, US

Market Capitalization: 144 678 257 000 $

Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.

EBITDA: 18 365 999 000 $

EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.

PE Ratio: 18.06

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.177

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0649

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 1.41

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: -0.982
Quarterly Revenue Growth YOY: 0.312
Trailing PE: 18.06

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 8.68

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3.164

Enterprise Value (EV) /Revenue

EV To EBITDA: 12.28

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 5666990000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Pfizer (PFE) stock dividend

Pfizer last paid dividends on 01/24/2025. The next scheduled payment will be on 03/07/2025. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Pfizer Stock)

Should I Buy Pfizer Shares in 2025 year?

The maximum forecasted share price for next year is $26.66, which is $1.02 higher than the current stock price. By investing in Pfizer shares today for a one-year period, you could achieve a profit of 3.98%. With an investment horizon of up to two years, the target share price is $29.34. resulting in a profit of 14.42% ($3.70 per share).

Does Pfizer pay dividends?

No, it does not

Which economic sector do Pfizer's shares belong to?

Pfizer's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Pfizer's shares?

You can view all the stocks that are part of the same sector as Pfizer's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.